منابع مشابه
Ibrutinib for the treatment of mantle cell lymphoma.
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma. It can follow a heterogeneous clinical course but generally patients relapse early after standard immunochemotherapy regimens and develop resistance to subsequent therapies. For younger patients, intensive approaches followed by autologous stem cell transplantation offer excellent long-term disease control but w...
متن کاملIbrutinib for a Paraneoplastic Polyneuropathy in Mantle Cell Lymphoma
Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma. Paraneoplastic disease with central nervous system involvement is a rare complication. Immunosuppression for the paraneoplastic features and chemotherapy for the underlying malignancy are described treatments but benefits are often short-lived because of co-morbid complications and disease resistance. This report descri...
متن کاملIbrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A continuing education article for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians The purpose of this article is to provide advanced practitioners with important information about new treatment options for mantle cell lymphoma and chronic lymphocytic leukemia, including novel oral agents,...
متن کاملTargets for Ibrutinib Beyond B Cell Malignancies
Ibrutinib (Imbruvica™) is an irreversible, potent inhibitor of Bruton's tyrosine kinase (BTK). Over the last few years, ibrutinib has developed from a promising drug candidate to being approved by FDA for the treatment of three B cell malignancies, a truly remarkable feat. Few, if any medicines are monospecific and ibrutinib is no exception; already during ibrutinib's initial characterization, ...
متن کاملRituximab for Mantle Cell Lymphoma
MCL usually responds to chemotherapy, only to relapse frequently, with a much shorter duration of response, time to progression, and overall survival compared to follicular NHL. The treatment approach for newly diagnosed patients generally depends on whether they are transplant-eligible. Only a small minority of patients achieve sustained remission after first-line therapy, and sequential thera...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Hematologist
سال: 2018
ISSN: 1551-8779
DOI: 10.1182/hem.v15.2.8303